Quantcast

Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus

November 6, 2009

SPRING VALLEY, Calif., Nov. 6 /PRNewswire/ — Calbiotech, Inc. announced today that it has been awarded a Small Business Innovative Research (SBIR) Phase I contract by the U.S. Army Medical Research and Material command. Under terms of the agreement, Calbiotech will develop analyte specific reagents (ASRs) for the diagnosis of Dengue virus.

Dengue virus is a mosquito-born flavivirus that represents a major threat to military forces deployed to tropical areas of the world. Due to its worldwide distribution, U.S. military and civilian personnel deployed overseas are at high risk of being infected. The global prevalence of Dengue has grown dramatically in recent decades, spreading from 9 to some 40 countries. The disease is now endemic in more than 100 countries in Africa, the Americas, the Eastern Mediterranean, Southeast Asia and the Western Pacific. Not only is the number of cases increasing as the disease is spreading to new areas, but explosive outbreaks are occurring. In 2007, Venezuela reported over 80 000 cases.

Technology developed under this research project will enable an affordable FDA-approved method for diagnosing Dengue fever in blood/sera. This will enable medical personnel to adequately diagnose and react to Dengue fever outbreaks.

This Phase I award will allow Calbiotech to compete for $730,000 in Phase II funding. A Phase II project would expand the work to develop ASRs for Rift Valley fever, Sand Fly fever-Toscana, Crimean-Congo fever, Central European Tick-borne encephalitis and Chikungunya viruses in blood/sera from clinically ill patients.

ABOUT CALBIOTECH: Calbiotech is a worldwide provider of Immunoassay products and services. The company offers ELISA, lumELISA(TM) (Ultra-Sensitive Chemiluminescent ELISA) and Radioimmunoassay (RIA) products, as well as preclinical testing services. Calbiotech’s product line includes: Endocrine, Steroid, Fertility, Cancer, Thyroid and Cardiac, Infectious Disease, Growth Hormone, Allergy and Drug of Abuse markers. The company also offers customized Immunoassay products for Mouse/Rat, Sheep, Canine, Porcine and other animal species that are used by major pharmaceutical companies, universities and research centers.

Calbiotech provides preclinical and research testing services for testing human and animal samples using the Calbiotech Immunoassay menu. Calbiotech is FDA registered and ISO 13485:2003 certified facility. The company has adopted operating polices based on FDA Quality system (QS), current Good manufacturing Practices (cGMP), Good laboratory Practices (GLP) and ISO requirements, EU directive and Canadian medical devices regulations.

Additional information is available on the Internet at http://www.calbiotech.com.

For more information, contact David Barka at Calbiotech, 10461 Austin Drive Spring Valley, CA, 91978 USA. Phone: (619) 660-6162. Fax: (619) 660-6970. E-mail: dbarka@calbiotech.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.

SOURCE Calbiotech, Inc.


Source: newswire



comments powered by Disqus